AMMONIA N 13- nh3n13 injection

Country: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

AMMONIA N-13 (UNII: 9OQO0E343Z) (AMMONIA N-13 - UNII:9OQO0E343Z)

Fáanlegur frá:

Essential Isotopes

INN (Alþjóðlegt nafn):

AMMONIA N-13

Samsetning:

AMMONIA N-13 260 mCi in 1 mL

Stjórnsýsluleið:

INTRAVENOUS

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Ammonia N 13 Injection USP is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. None Pregnancy Category C Animal reproduction studies have not been conducted with Ammonia N 13 Injection.  It is also not known whether Ammonia N 13 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Ammonia N 13 Injection should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from Ammonia N 13 Injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for N 13 isotope) after administration of the drug or avoid use of the drug, taking

Vörulýsing:

Ammonia N 13 Injection USP is packaged in 30 mL multiple dose glass vial containing between 1.11 GBq to 48.1 GBq (30 mCi to 1300 mCi) of [13 N] ammonia, at the end of synthesis (EOS) reference time, in 0.9% sodium chloride injection solution in approximately 8 mL volume.  The recommended dose of radioactivity (10-20 mC, 370 to 740 MBq) is associated with a theoretical mass dose of 0.5-1.0 picomoles (8.47-16.94 picograms) of Ammonia. Handling Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the US Nuclear Regulatory Commission, Agreement states or licensing states as appropriate. Storage Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).Use the solution within 90 minutes of the End of Synthesis (EOS) calibration.

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

AMMONIA N 13 - NH3N13 INJECTION
ESSENTIAL ISOTOPES
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
AMMONIA N 13 INJECTION
USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
AMMONIA N 13 INJECTION
USP.
AMMONIA N 13 INJECTION FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 2007
INDICATIONS AND USAGE
Ammonia N 13 Injection is a radioactive diagnostic agent for Positron
Emission Tomography (PET)
indicated for diagnostic PET imaging of the myocardium under rest or
pharmacologic stress conditions to
evaluate myocardial perfusion in patients with suspected or existing
coronary artery disease (1).
DOSAGE AND ADMINISTRATION
Rest Imaging Study (2.1):
Aseptically withdraw Ammonia N 13 Injection from its container and
administer 10-20 mCi (0.368 –
0.736 GBq) as a bolus through a catheter inserted into a large
peripheral vein.
Start imaging 3 minutes after the injection and acquire images for a
total of 10-20 minutes.
Stress Imaging Study (2.2):
If a rest imaging study is performed, begin the stress imaging study
40 minutes or more after the first
Ammonia N13 injection to allow sufficient isotope decay.
Administer a pharmacologic stress-inducing drug in accordance with its
labeling.
Aseptically withdraw Ammonia N 13 Injection from its container and
administer 10-20 mCi (0.368 –
0.736 GBq) of Ammonia N 13 Injection as a bolus at 8 minutes after the
administration of the
pharmacologic stress-inducing drug.
Start imaging 3 minutes after the Ammonia N 13 Injection and acquire
images for a total of 10-20
minutes.
Patient Preparation (2.3):
To increase renal clearance of radioactivity and to minimize radiation
dose to the bladder, hydrate the
patient before the procedure and encourage voiding as soon as each
image acquisition is completed
and as often as possible thereafter for at least one hour.
DOSAGE FORMS AND STRENGTHS
Vial containing 0.139-9.620 GBq (3.75-260 mCi/mL) of Ammonia N 13
Injection USP in aqueous 0.9 %
sodium chloride solution (approxima